Royalty Report: Medical, Therapeutic, Device – Collection: 28986

The agreement also includes a non-exclusive license to the copyright over certain user interface software for controlling and monitoring nerve stimulation. The agreement allows for sublicensing.

Sleep Disorders. One innovation consists of technology designed to take advantage of the fact that signals from the limbs interpreted by the brain as movement can elicit enhanced breathing rates. The device we would expect to develop would use a nerve stimulation technique to enhance the breathing rate without actual limb movement. The target market for the commercialization of this technology would include people who suffer sleep disorders mostly due to irregular breathing, the most common of which is sleep apnea.

Provisional Patent Application No. 61/856,883 entitled, 'Device, System and Method for Facilitating Breathing Via Stimulation of Limb Movement'

Patent Cooperation Treaty Application No. PCT/US14/047642 entitled, 'Device, System and Method for Facilitating Breathing Via Simulation of Limb Movement'

“Copyright: Graphical User Interface Software to Control and Monitor Nerve Stimulation Device'

The University's hereby grants to Licensee a non-exclusive license (the 'Copyright License') under Regents' Copyright Rights, in jurisdictions where the University's Copyright Rights exist, to use, produce, copy, reproduce, display, create derivative works of, perform, and distribute the Licensed Copyright Products in the Field of Use to the extent permitted by law.

The University's grants to Licensee the right to sublicense the University's Patent Rights granted to Licensee.

Head Pain Management. The other innovation consists of technology designed to take advantage of the fact that stimulating the sensory fibers of a nerve can mask pain perception. The technology uses mechanical vibration (as opposed to electrical stimulation) to stimulate such fibers and is non-invasive and patient controllable. The target market for the commercialization of this technology would include migraine sufferers; those with trigeminal neuropathy, a debilitating, long-lasting oral pain, often arising from failed or compromised dental procedures; and others.

Provisional Patent Application No. 61/905,616 entitled, 'Device, System and Method for Reducing Headache Pain,' filed November 18th, 2013

“Copyright: Graphical User Interface Software to Control and Monitor Nerve Stimulation Device'

For the Evaluation License Grant, Licensor grants, during the Option Period, a non-exclusive, limited research-use only license, without the right to sublicense, except to subcontractors as provided in this Agreement, under the Licensor Technology solely to perform Preliminary Evaluation Work and Evaluation Studies as provided in this Agreement.

For the Muscarinic Product Development and Commercialization License, Licensor grants, during the Term, an exclusive, worldwide license, with the right to sublicense even through multiple tiers of sublicense, under Licensor Technology and Licensor’s interest in Joint Patents, to develop, make, have made, use, distribute, promote, sell, offer for sale, have sold, import, and export Muscarinic Products in the Muscarinic Field.

For the Fixed Co-Formulation Product Development and Commercialization Exclusive License, effective only upon exercise of the Option and payment in full of the Option Exercise Fee, Licensor grants, during the Term, an exclusive, worldwide license, with the right to sublicense even through multiple tiers of sublicense, under Licensor Technology to develop, make, have made, use, distribute, promote, sell, offer for sale, have sold, import, and export Fixed Co-Formulation Products in the Sleep Field. For the avoidance of doubt, the license granted excludes any license under Licensor Technology to develop, make, have made, use, distribute, promote, sell, offer for sale, have sold, import, and export N-Dealkylated Licensed Compound Metabolites, and any license under Licensor Technology containing claims directed only to N-Dealkylated Licensed Compound Metabolites.

For the Fixed Co-Formulation Product Development and Commercialization Non-Exclusive License, Licensor grants, during the Term, a non-exclusive, worldwide license, with the right to sublicense even through multiple tiers of sublicense, under Licensor Technology and any other Patents directed to N-Dealkylated Licensed Compound Metabolites that are Controlled by Licensor to develop, make, have made, use, distribute, promote, sell, offer for sale, have sold, import, and export Fixed Co-Formulation Products in the Sleep Field.

For the Grant of Option, Licensor grants an option, exercisable during the Final Evaluation Period with respect to one (1) Chosen Compound, to obtain an exclusive, worldwide license, with the right to sublicense, under the Licensor Technology to develop, make, have made, use, distribute, distribute for sale, promote, sell, offer for sale, have sold, or import Fixed Co-Formulation Products in the Sleep Field.

The Licensor Know-How, beyond the patents, during the research term, excludes any such information relating to Licensors compounds known as -103 and -104, -104 Analogs and/or Topical Eyecare Compounds, which is Confidential Information of Licensor.

Licensor Muscarinic Compounds shall mean any compound Controlled by Licensor on the Effective Date, the primary mode of action of which is [activity as a selective] allosteric modulator, agonist, or antagonist of any one (1) or more of the five (5) muscarinic receptor subtypes, including, without limitation, Licensors proprietary [m3 antagonists), but subject to exclusion of [m1] Agonists.  Notwithstanding the foregoing or any other provision of this Agreement to the contrary, neither Licensors compound known as -104 (N-desmethylclozapine) nor any -104 Analogs shall be considered Licensor Muscarinic Compounds for purposes of this Agreement.

Muscarinic receptors are receptors that respond to acetylcholine, a neurotransmitter in the central nervous system.

Sleep Field shall mean the treatment, prevention, or management, or any combination thereof, as a primary objective, of any condition, disturbance, disease, or disorder in humans the principal effect(s) of which are on sleep time, sleep quality, sleep onset, sleep architecture, or sleep maintenance, or to disrupt or disturb normal sleep or sleep patterns, including without limitation: insomnia, including without limitation transient, chronic, primary, and secondary insomnia; jet lag; bruxism; breathing related sleep disorders, including without limitation sleep apnea; sleep terror disorders, including sleep terrors and pavor nocturnus; sleep walking disorders; sleep paralysis; circadian rhythm sleep disorders, including without limitation delayed sleep phase syndrome, and advanced phase sleep syndrome; shift work sleep disorder; sleep enuresis; sudden infant death syndrome; narcolepsy; periodic limb movement disorder; rapid eye movement behavior disorder; other parasomnias; and other dysomnias, and also including, without limitation, any such condition, disturbance, disease, or disorder where the treatment, prevention, or management, or any combination thereof, of any such condition, disturbance, disease, or disorder may result, as a secondary objective, in [improving cognitive function, alertness, physical dexterity, coordination, symptoms of fatigue, and other detrimental symptoms associated with or arising from any of the foregoing conditions, disturbances, diseases, or disorders.

The vagus nerve, historically cited as the pneumogastric nerve, is the tenth cranial nerve or CN X, and interfaces with the parasympathetic control of the heart, lungs, and digestive tract. The vagus nerves are paired but are normally referred to in the singular.

Licensed Patents means the NS, the Feinstein Institute for Medical Research, formerly known as North Shore Long Island Jewish Research Institute licensed Patents.

The patents include Inhibition of Inflammatory Cytokine Production by Stimulation of Brain Muscarinic Receptors, and, Cholinergic Agonists and Vagus Nerve Stimulation, and, Neural Tourniquet.

Vagus nerve stimulation is a medical treatment that involves delivering electrical impulses to the vagus nerve. It is used as an add-on treatment for certain types of intractable epilepsy and treatment-resistant depression. Frequent side effects include coughing and shortness of breath.

Technology:
Oscillating Field Stimulation (OFS)
Oscillating Field Stimulation and a Growth Factor
4-AP Derivatives
Hydralazine
Hydralazine + PEG
PEG for Vascular Leakage
Double Sucrose Gap Recording Apparatus
Coherent Anti-Stokes Raman Scattering

Licensed IP shall mean all know-how, technical information, copyrights and renewals, designs, drawings, specifications, manufacturing methods, and all other information owned by Foundation and related to the Technologies.

Licensed Patents shall mean all U.S. patent applications, Patent Cooperation Treaty patent applications, or foreign patent applications filed by Foundation and related to a Technology, and all divisionals, continuations, continuations-in-part, or other patent applications that claim priority from such patent applications; any patent(s) issuing from the foregoing applications and all extensions, reexaminations, and reissues of such patent(s); and any patents issuing from patent applications that are related to a Technology and that are filed by Foundation subsequent to the Effective Date, and all extensions, reexaminations, and reissues of such patents.

4,919,140 – Method and apparatus for regenerating nerves

OFS + Inosine Technology means the technology  No 62139, US Patent Application No. 10/748,572 and /or PT Patent Application No. PCT/US2003/01480.